Simon F. Shakar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simon F. Shakar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Brian D. Lowes
Department of Cardiology, University of Nebraska Medical Center, Omaha, USA
2 shared publications Alastair D. Robertson
Department of Medicine, Division of Cardiology, University of Colorado at Denver and Health Sciences Center, Denver, Colorado
1 shared publication- Andreas Brieke
University of Colorado (RLP, AB, JL), University of Colorado Hospital (ML), Aurora
1 shared publication Anne Cannon
Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado at Denver and Health Sciences Center, Denver, Colorado
1 shared publication- David A. Fullerton
Division of Cardiothoracic Surgery, University of Colorado School of Medicine, Aurora, Colo
1 shared publication David N. Campbell
Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado at Denver and Health Sciences Center, Denver, Colorado
1 shared publication
Latest Publications
- 30 September 2008
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 136 (3) , 774-777
Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival
- 30 September 2008
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 136 (3) , 774-777
Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival
- Open Access
- 1 January 2008
- Published by Springer Nature in Critical Care
- Vol. 12 (5) , 177
Myocardial protection in sepsis
Sepsis with myocardial dysfunction is seen commonly. Beta-blockers have been used successfully to treat chronic heart failure based on the premise that chronically elevated adrenergic drive is detrimental to the myocardium. However, recent reports on the acute use of beta-blockers in situations with potential hemodynamic compromise have shown the risks associated with this approach. In critical situations, the main effect of adrenergic activation is to support cardiovascular function. Caution should be exercised in designing studies to assess beta-blockers in septic patients.
- 1 January 2008
- Published by Springer Nature in Critical Care
- Vol. 12 (5) , 177
Open AccessMyocardial protection in sepsis
Sepsis with myocardial dysfunction is seen commonly. Beta-blockers have been used successfully to treat chronic heart failure based on the premise that chronically elevated adrenergic drive is detrimental to the myocardium. However, recent reports on the acute use of beta-blockers in situations with potential hemodynamic compromise have shown the risks associated with this approach. In critical situations, the main effect of adrenergic activation is to support cardiovascular function. Caution should be exercised in designing studies to assess beta-blockers in septic patients.